Dr Tatyana Shelkovnikova


Department of Neuroscience

UKRI Future Leaders Fellow (Senior Research Fellow)

+44 114 22 22270

Full contact details

Dr Tatyana Shelkovnikova
Department of Neuroscience
Sheffield Institute for Translational Neuroscience (SITraN)
385a Glossop Road
S10 2HQ

After graduating with an MSc degree in Genetics in 2008, I pursued a PhD in Biochemistry which I completed in 2012. During my PhD training, supported by an EMBO fellowship, I contributed to the generation and characterisation of a unique mouse model of a fatal neurodegenerative disease, amyotrophic lateral sclerosis (ALS); report on this mouse model published in J Biol Chem was selected as Paper of the Year. I continued to develop this stream of research during my postdoctoral training at Cardiff University (Prof Buchman’s lab), where I spearheaded a number of projects focussing on (dys)metabolism of ribonucleoprotein (RNP) granules in ALS. In 2015, these studies were supported by a 3-year fellowship from the Medical Research Foundation. In 2018, I was awarded a 4-year senior non-clinical fellowship from the MND Association and started my own group at the Medicines Discovery Institute, a newly established Cardiff University’s translational unit. During my time at the MDI, my research was supported by AMS Springboard award, the ISSF Translational Kick-Start award and funding from Welsh Government. I am the recipient of the ENCALS Young Investigator award 2020. In September 2021, I moved to SITraN, University of Sheffield, to continue studies into the molecular pathogenesis of ALS and related disorders within a world-leading centre for neurodegenerative disease research. In May 2022, I was awarded the UKRI Future Leaders Fellowship to establish a research programme entitled “RNA-protein complexes in health and disease and their therapeutic targeting”. The group is also currently funded by MNDA, BBSRC, MRC and MND Scotland.

Research interests

My group aims to provide insights into molecular underpinnings of RNP granule biology and their connection to human disease. Our overarching goals are:

  • to establish how altered composition and metabolism of the two types of RNP granules, stress granules and paraspeckles, contribute to the pathogenesis of ALS and frontotemporal dementia (FTD);
  • to discover and validate druggable targets for these devastating and currently incurable conditions;
  • to identify novel chemical probes for modulation of RNAs and RNP complexes.

Journal articles


Research group

Wan-Ping Huang (PDRA)

Rachel Hodgston (PDRA)

Zhaklin Chalakova (research assistant)

Vedanth Kumar (technician)

Jessica Rayment (technician)

Brittany Ellis (PhD student)

Teaching interests

I am the lead on Phase 2A Research Attachment SSC for the Department of Neuroscience.

My lab also hosts postgraduate (MSc, Neuroscience, Oncology & Metabolism, visiting) students.

Professional activities and memberships
  • Regularly solicited to review grant applications and manuscripts.
  • Grants: MND Association; MRC; BBSRC; Strasbourg Institute for Advanced Studies (USIAS); Worldwide Cancer Research; French National Research Agency (ANR); Research Foundation Flanders’ (FWO); Israel Science Foundation; French Research Association on ALS; European Science Foundation.
  • Manuscripts: reviewed for >30 journals, including Nat Neurosci, Nat Commun; Trends Genet; J Cell Biol, EMBO Rep, Cell Rep. >40 papers, for full list– see Publons.
  • Acted as external PhD examiner for students at the University College London / Crick Institute and King’s College London.
  • Invited to speak at multiple departmental seminars (including UCL, universities in Australia, Japan, Italy, Russia) and conferences.
  • Participated in outreach events and patient-oriented activities, including demonstration at science festivals and MND guest research blog writing.
Current Projects
  • Regulation of RNP granules paraspeckles and stress granules under acute and chronic stress and in disease states (cellular models) - funded by the MND Association and BBSRC.
  • Mechanistic studies of the RNA-binding proteins FUS and TDP-43 in ALS and FTD – funded by MRC.
  • Therapeutic targeting of RNA and RNA-protein complexes (assay development and screening activities) – funded UKRI FLF and MRC.
  • Targeting axonal dysfunction in ALS by small molecule splicing correction – funded by MND Scotland.